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Detecting Diffuse Myocardial Fibrosis With CMR
The Future Has Only Just Begun*Theodoros D. Karamitsos, MD, PHD, Stefan Neubauer, MDOxford, United KingdomThe development of late gadolinium enhancement
imaging (LGE) in the late 1990s revolutionized
the clinical application of cardiovascular magnetic
resonance (CMR) in ischemic and nonischemic
cardiomyopathies (1). Not only has the identiﬁca-
tion of even small subendocardial myocardial in-
farcts become possible due to the unsurpassed
spatial resolution of the technique, but also speciﬁc
patterns of ﬁbrosis have enabled a detailed
phenotypic characterization of many nonischemic
cardiomyopathies (2). More recently, the prog-See page 672nostic capability of LGE-CMR to predict adverse
outcomes has been demonstrated (3,4). However,
as with every imaging technique, signiﬁcant limi-
tations of LGE soon became apparent. One
inherent limitation is that LGE relies on the signal
intensity difference between ﬁbrotic and normal
myocardial tissue, and hence a region of “normal”
nulled myocardium is needed as a reference to
detect abnormalities (5). This limits the ability of
LGE to detect diffuse, homogeneously distributed
ﬁbrosis, which, according to histopathological
studies, is a main feature in many forms of heart
disease (6,7).*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
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to disclose.An exciting recent development in CMR is
the advent of techniques that provide quantitative
information on diffuse myocardial ﬁbrosis (8).
These techniques measure the intrinsic magnetic
resonance relaxation parameter T1 of the myocar-
dium and map its spatial distribution (T1 map-
ping). The measured differences in R1 (¼ 1/T1)
values pre- and post-gadolinium contrast allow
quantiﬁcation of the myocardial extracellular vol-
ume fraction (ECV), which is increased in the
presence of diffuse ﬁbrosis (9–13). Currently, there
are 3 CMR techniques of ECV quantiﬁcation,
which differ in the way in which they account for
the confounding effect of contrast kinetics (8). The
ﬁrst method, pioneered by Kellman and Arai (13),
assumes that after sufﬁcient time has lapsed, a dy-
namic equilibrium in contrast concentration be-
tween blood and myocardium is reached and
therefore only 2 T1 measurements before and w15
to 20 min after contrast are sufﬁcient to measure
ECV. The second technique, pioneered by Jerosch-
Herold (9,12), requires multiple (typically 3 to 5)
post-contrast T1 measurements spanning a 30-min
period. The third technique, pioneered by Moon
(10), uses a contrast bolus followed by a slow
infusion for 30 to 60 min of the same contrast agent
to induce contrast equilibrium between vascular
and interstitial space. For all methods, a measure-
ment of the blood volume of distribution (equal to
1-hematocrit) is needed to calculate ECV. Nonin-
vasive calculation of ECV is an exciting new
development in CMR, which opens new frontiers
for research.
In this issue of iJACC, Neilan et al. (14) provide
further insights into the distribution of ECV
values in a healthy population, and they also pro-
vide histological validation of ECV measurements
in mice. A multimeasurement post-contrast T1
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685mapping method was used in both humans and
mice. The authors studied 32 well-deﬁned healthy
volunteers at 3-T and describe a relatively narrow
range of ECV measurements (from 0.23 to 0.33,
mean 0.28  0.03). There was no difference in
myocardial ECV between basal, mid, and apical
left ventricular slices or between left ventricular
segments (e.g., septum vs. anterior vs. inferior vs.
lateral wall) within a slice. The interobserver and
intraobserver variability and the test-retest differ-
ence of ECV measurements were small, which is
important for the validity of follow-up studies.
Furthermore, there was no sex-associated differ-
ence in myocardial ECV, but there was a signiﬁ-
cant positive correlation between myocardial ECV
and age (r ¼ 0.74, p < 0.001) in humans. In mice,
there was a strong association between myocardial
ECV and the histological extent of ﬁbrosis (r ¼
0.94, p < 0.001). The authors concluded that
ECV imaging is a useful index for noninvasively
measuring myocardial ﬁbrosis in vivo, thus
demonstrating the promise of further application
of the technique in patients with cardiovascular
disease.
A major strength of this excellent study is the
application of a robust T1 imaging protocol for
ECV quantiﬁcation, which extends a conventional
CMR scan by only 5 to 10 min. Another strength is
the histological validation of ECV measurements
in mice, although, as the authors acknowledge,
important biological differences may exist regarding
the effect of aging in rodents compared with
humans. The authors conﬁrm recent data regarding
the relationship between ECV and aging: Ugander
et al. (13) studied 60 patients with known or sus-
pected heart disease but no discernible LGE and
measured ECV using a single pre- and post-
contrast T1 protocol. They found a modest,
although signiﬁcant, relationship between ECV and
age (r ¼ 0.28, p ¼ 0.01), which was, however, much
weaker than that reported by Neilan et al. (14). A
possible explanation for this discrepancy is that
Ugander et al. (13) included patients with risk fac-
tors such as diabetes, hypertension, and hyperlip-
idemia, whereas Neilan et al. (14) only studied
healthy volunteers. A limitation of the present study
is the small sample size of the human cohort (n ¼
32), and further large-scale studies are needed to
fully establish a database for age- and sex-speciﬁc
normality of cardiac ECV measurements. Despite
this limitation, the study by Neilan et al. (14) further
expands our knowledge of ECV imaging in normal
subjects and is an important contribution to this
evolving ﬁeld.To date, T1 mapping/ECV results have been
reported for small groups of selected patients with
acute myocardial infarction (15,16), chronic
myocardial infarction (16), acute myocarditis (17),
aortic stenosis (18), hypertrophic cardiomyopathy
(10), congenital heart disease (9), idiopathic
dilated cardiomyopathy (11,12) and inﬁltrative
heart disease (19,20). These studies have provided
interesting preliminary insights into diffuse ﬁbrosis
detection with CMR, supported by histological
validation in aortic stenosis, hypertrophic cardio-
myopathy, and dilated cardiomyopathy. However,
they have also highlighted several unresolved is-
sues. First, and perhaps most important, the se-
lection of T1 mapping sequence is crucial because
different T1 mapping sequences have varying
sensitivity to motion artifacts, heart rate, and
native myocardial T1 value ranges. Newer fast T1
mapping sequences show improved clinical appli-
cability (shorter breath-hold) and are robust even
at high heart rates (21). Furthermore, with the use
of rapid T1 mapping methods, current single-slice
or 3-slice acquisition protocols will give way to
whole-heart, multislice approaches. Most recently,
non–breath-hold techniques with motion correc-
tion have also become available (22). Furthermore,
T1 mapping without the use of gadolinium
contrast can also detect diffuse ﬁbrosis-associated
changes (23), and this method could become
particularly useful for patients with contraindica-
tions to gadolinium administration. As with every
imaging method, widespread clinical applicability
of ECV imaging will only become reality if current
ECV acquisition methods are standardized and
developed as a universally accepted rapid, robust
protocol. As an imaging community, we have to
embrace this challenge. Several important steps
have already been made toward this goal, such as
the demonstration that ECV estimation is gado-
linium dose independent and that the infusion and
bolus techniques yield similar ECV measurements
(14,15). Post-processing, which is currently based
on time-consuming manual contouring, should also
improve and include contour detection algorithms.
Last, ECV imaging should further expand to
include hypertensive heart disease, diabetic cardio-
myopathy, sarcoidosis, or other less common car-
diomyopathies, bearing in mind that interstitial
space expansion is not a speciﬁc response to ﬁbrosis,
but inﬁltration (e.g., due to amyloid deposition) or
edema may also lead to ECV increases (19).
Therefore, future clinical studies will need to be
conducted in well-deﬁned patient populations and
provide histological validation whenever possible.
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686The future of diffuse ﬁbrosis imaging is bright,
and these exciting new developments underscore the
main advantage that CMR has over other imaging
modalities, namely, its ability to provide detailed
in vivo myocardial tissue characterization. Diffuse
ﬁbrosis and ECV quantiﬁcation may become
powerful imaging biomarkers for the assessment of
prognosis and for monitoring the effects of current
(e.g., angiotensin-converting enzyme inhibitors,aldosterone receptor blockers) and novel antiﬁbrotic
therapies.Reprint requests and correspondence: Dr. Stefan
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